CN112654395A - 定量lif的方法及其用途 - Google Patents

定量lif的方法及其用途 Download PDF

Info

Publication number
CN112654395A
CN112654395A CN201980053683.8A CN201980053683A CN112654395A CN 112654395 A CN112654395 A CN 112654395A CN 201980053683 A CN201980053683 A CN 201980053683A CN 112654395 A CN112654395 A CN 112654395A
Authority
CN
China
Prior art keywords
lif
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980053683.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·赛瓦内苏阿雷斯
J·阿尼多福尔盖拉
P·A·吉布林
P·E·拜利斯
J·弗兰松
A·热塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, MedImmune Ltd filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of CN112654395A publication Critical patent/CN112654395A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
CN201980053683.8A 2018-06-18 2019-06-17 定量lif的方法及其用途 Pending CN112654395A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382433.3 2018-06-18
EP18382433 2018-06-18
PCT/IB2019/000756 WO2019243893A1 (en) 2018-06-18 2019-06-17 Methods of quantifying lif and uses thereof

Publications (1)

Publication Number Publication Date
CN112654395A true CN112654395A (zh) 2021-04-13

Family

ID=62716028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053683.8A Pending CN112654395A (zh) 2018-06-18 2019-06-17 定量lif的方法及其用途

Country Status (5)

Country Link
US (1) US20210190798A1 (https=)
EP (1) EP3806960A1 (https=)
JP (1) JP7570929B2 (https=)
CN (1) CN112654395A (https=)
WO (1) WO2019243893A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116298320A (zh) * 2023-03-31 2023-06-23 深圳迈瑞生物医疗电子股份有限公司 检测白血病抑制因子的试剂盒及检测方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020354255A1 (en) 2019-09-29 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for LIF and use thereof
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057144A2 (en) * 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM K J ET AL.: "Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA", 《JOURNAL OF IMMUNOLOGICAL METHODS》, vol. 156, no. 1, pages 11 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116298320A (zh) * 2023-03-31 2023-06-23 深圳迈瑞生物医疗电子股份有限公司 检测白血病抑制因子的试剂盒及检测方法
CN116298320B (zh) * 2023-03-31 2025-07-11 深圳迈瑞生物医疗电子股份有限公司 检测白血病抑制因子的试剂盒及检测方法

Also Published As

Publication number Publication date
EP3806960A1 (en) 2021-04-21
JP7570929B2 (ja) 2024-10-22
WO2019243893A1 (en) 2019-12-26
JP2021528411A (ja) 2021-10-21
US20210190798A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US10206999B2 (en) Antibodies against LIF and uses thereof
KR102599557B1 (ko) Lif에 대한 항체 및 이의 용도
JP7570929B2 (ja) Ｌｉｆを定量化する方法及びその使用
CN112638941A (zh) 针对lif的抗体及其剂量形式
AU2019291305B2 (en) Methods for improving response to anti-LIF antibody treatment in individuals with cancer
HK40051946A (en) Methods of quantifying lif and uses thereof
HK40042216A (en) Antibodies against lif and dosage forms thereof
HK40051950A (zh) 用於改善患有癌症的个体对抗lif抗体治疗的反应的方法
EA049383B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
EA044914B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
HK40056275A (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
KR20210022065A (ko) 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
EA045781B1 (ru) Антитела к lif и их применения
EA051297B1 (ru) Антитела к lif и их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051946

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413

WD01 Invention patent application deemed withdrawn after publication